Company news: Bausch + Lomb and ISTA; Sanofi and Regeneron

Share this article:
Eye care giant Bausch + Lomb is buying ISTA Pharmaceuticals for $500 million. ISTA brings to Bausch + Lomb a portfolio of eye health drugs including non-steroidal, anti-inflammatory, allergy, glaucoma and spreading agents. ISTA's pipeline, featuring therapies to treat inflammation and pain, complements Bausch + Lomb's, which includes the first of a new class of ocular anti-inflammatory agents to come along in decades, said the companies. The transaction is subject to regulatory approval and the assent of ISTA's shareholders.

Sanofi and Regeneron's experimental cholesterol drug lowers LDL cholesterol by up to 72% in a Phase 2 trial involving 183 patients, the companies reported at the American College of Cardiology meeting in Chicago. The drug is one of a new class called PCSK9 inhibitors, including compounds in development by Amgen, Pfizer and Merck.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.